Curriculum Vitae
Tomás Fonseca
Identification
Personal identification
- Full name
- Tomás Fonseca
Citation names
- Fonseca, Tomás
Author identifiers
- Ciência ID
- 8C1B-F9C7-F700
- ORCID iD
- 0000-0002-9386-1250
Email addresses
- tomasfonseca.medicina@chporto.min-saude.pt (Professional)
Addresses
- Largo do Prof. Abel Salazar, 4099-001, Miragaia, Porto, Portugal (Professional)
Knowledge fields
- Medical and Health Sciences - Clinical Medicine
- Medical and Health Sciences - Clinical Medicine - General and Internal Medicine
Languages
| Language | Speaking | Reading | Writing | Listening | Peer-review |
|---|---|---|---|---|---|
| Portuguese (Mother tongue) | |||||
| English | Proficiency (C2) | Proficiency (C2) | Advanced (C1) | Proficiency (C2) | Advanced (C1) |
| Spanish; Castilian | Intermediate (B1) | Upper intermediate (B2) | Elementary (A2) | Upper intermediate (B2) | Elementary (A2) |
| French | Elementary (A2) | Elementary (A2) | Beginner (A1) | Elementary (A2) | Beginner (A1) |
Education
| Degree | Classification | |
|---|---|---|
|
2014/01/01 - 2018/12/31
Concluded
|
Especialidade Medicina Interna (Título de especialista)
Centro Hospitalar Universitário do Porto EPE, Portugal
|
19.6 |
|
2017/09/29 - 2018/07/08
Concluded
|
8ª pós-graduação em Medicina do Doente Crítico (Pós-Graduação)
Reanima, Portugal
|
Apto |
|
2006/09/01 - 2012/07/01
Concluded
|
Medicina (Mestrado integrado)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
"Testes preditivos na abordagem de via aérea difícil: Um estudo retrospectivo na cirurgia maxilo-facial" (THESIS/DISSERTATION)
|
15 |
Affiliation
Teaching in Higher Education
| Category Host institution |
Employer | |
|---|---|---|
| 2015/09/01 - Current | Invited Assistant (University Teacher) | Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal |
| Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal |
Others
| Category Host institution |
Employer | |
|---|---|---|
| 2019/01/01 - Current | Medical Doctor | Unidade Local de Saúde de Santo António EPE, Portugal |
| CHUP - Unidade Imunologia Clínica, Portugal | ||
| 2017/07/01 - Current | Consultant medical doctor | Centro Hospitalar Conde de Ferreira, Portugal |
| 2014/01/01 - Current | Medical Doctor | Unidade Local de Saúde de Santo António EPE, Portugal |
| 2013/01/01 - 2013/12/31 | Medical Doctor | Centro Hospitalar Tâmega e Sousa EPE, Portugal |
Projects
Contract
| Designation | Funders | |
|---|---|---|
| 2022/06 - Current | A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the
efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis
with Polyangiitis (EGPA) receiving SoC
NCT05263934
Principal investigator
CHUP - Unidade Imunologia Clínica, Portugal
|
Submitted
|
| 2021 - Current | 20170588: A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus
Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC)Therapy
NCT04058028
Subinvestigator
CHUP - Unidade Imunologia Clínica, Portugal
|
Ongoing
|
| 2020 - Current | SELUNE (CAIN457Q12301): A two-year, phase III randomized, double-blind, parallelgroup,placebo-controlled trial to evaluate
the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination with SoC therapy, inpatients
with active lupus nephritis; sponsor
NCT04181762
Subinvestigator
CHUP - Unidade Imunologia Clínica, Portugal
|
Ongoing
|
| 2020 - Current | MEADOW (B7931028): A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE
EFFICACY AND ¿ SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMICLUPUS ERYTHEMATOSUS (SLE)
NCT03845517
Subinvestigator
CHUP - Unidade Imunologia Clínica, Portugal
|
Ongoing
|
| 2017 - Current | Exceed - A randomized double-blind, active-conrol, multicenter study to evaluate the efficacy at week 52 of subcutaneously
administered secukinumab monotherapy compared with subcutaneously administered adalimumab monotherapy in patients with active
psoriatic arthritis.
NCT02745080
Subinvestigator
CHUP - Unidade Imunologia Clínica, Portugal
|
Concluded
|
| 2018 - 2021 | CVAY736A2201: A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and
efficacy of multiple ianalumab doses administered subcutaneously in patients with moderate to severeprimary Sjögren’s Syndrome
NCT02962895
Subinvestigator
CHUP - Unidade Imunologia Clínica, Portugal
|
Concluded
|
Outputs
Publications
| Conference paper |
|
| Journal article |
|
Activities
Oral presentation
| Presentation title | Event name Host (Event location) |
|
|---|---|---|
| 2021/11/20 | COVID-19 - Fator de risco Major para trombose | VI Reunião Anual do Núcleo de Estudos de Doença Vascular Pulmonar
Sociedade portuguesa de Medicina Interna (Portugal)
|
| 2021/02/27 | Caracterização doentes internados no Centro Hospitalar Universitário do Porto – 1ª vaga | VII Congresso Internacional de Cuidados Intensivos
(Portugal)
|
Association member
| Society Organization name | Role | |
|---|---|---|
| 2018 - Current | Sociedade Portuguesa Medicina Interna | Member |
| 2018 - Current | Nucleo Estudos Doenças Auto-Imunes (NEDAI) | |
| 2013 - Current | Ordem dos Médicos | Member |
Course / Discipline taught
| Academic session | Degree Subject (Type) | Institution / Organization | |
|---|---|---|---|
| 2017 - Current | Aulas de Imunologia Clínica | Medicina (Mestrado integrado) | Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal |
Mentoring / Tutoring
| Topic | Student name | |
|---|---|---|
| 2022/01/01 - 2026/12/31 | Internal Medicine speciality mentor | Catarina Romero Veiga |
| 2021/01/01 - 2025/12/31 | Internal Medicine speciality mentor | Marta Vaz Matos |
Distinctions
Award
| 2018 | Best Poster Presentation in the 11th European Lupus Meeting |